|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.800 CNY | +0.84% |
|
-0.21% | -13.20% |
| 05-25 | North China Pharma Gets China Nod for Kidney Anemia Drug | MT |
| 04-24 | North China Pharmaceutical Company.Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: North China Pharmaceutical Company.Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 16,781 | 20,452 | 10,981 | 9,780 | 8,870 | 9,488 |
| Change | - | 21.87% | -46.31% | -10.94% | -9.3% | 6.96% |
| Enterprise Value (EV) 1 | 25,126 | 28,923 | 20,346 | 19,939 | 18,660 | 19,162 |
| Change | - | 15.11% | -29.65% | -2% | -6.41% | 2.69% |
| P/E | 172x | 1,084x | -15.9x | 1,900x | 69.9x | 51.7x |
| PBR | 2.74x | 3.36x | 2.07x | 1.84x | 1.65x | 1.72x |
| PEG | - | -13.3x | 0x | -19x | 0x | 1.2x |
| Capitalization / Revenue | 1.46x | 1.97x | 1.05x | 0.97x | 0.9x | 1.03x |
| EV / Revenue | 2.19x | 2.79x | 1.94x | 1.97x | 1.89x | 2.07x |
| EV / EBITDA | 20.8x | 23.7x | 15.2x | 15.7x | 12.9x | 12.6x |
| EV / EBIT | 42x | 48.2x | 32.1x | 37.2x | 28.3x | 30.6x |
| EV / FCF | -30.9x | -32x | 112x | 128x | 49.1x | 35.2x |
| FCF Yield | -3.24% | -3.12% | 0.89% | 0.78% | 2.03% | 2.84% |
| Dividend per Share 2 | 0.03 | 0.06 | - | 0.01 | 0.03 | 0.035 |
| Rate of return | 0.29% | 0.5% | - | 0.18% | 0.58% | 0.63% |
| EPS 2 | 0.06 | 0.011 | -0.402 | 0.003 | 0.074 | 0.107 |
| Distribution rate | 50% | 545% | - | 333% | 40.5% | 32.7% |
| Net sales 1 | 11,493 | 10,385 | 10,500 | 10,120 | 9,870 | 9,242 |
| EBITDA 1 | 1,209 | 1,221 | 1,343 | 1,272 | 1,447 | 1,517 |
| EBIT 1 | 597.9 | 600.1 | 634.8 | 536.4 | 658.9 | 627.2 |
| Net income 1 | 97.32 | 18.73 | -689.2 | 4.89 | 127 | 183.1 |
| Net Debt 1 | 8,345 | 8,472 | 9,366 | 10,159 | 9,790 | 9,674 |
| Reference price 2 | 10.290 | 11.920 | 6.400 | 5.700 | 5.170 | 5.530 |
| Nbr of stocks (in thousands) | 1,630,805 | 1,715,730 | 1,715,730 | 1,715,730 | 1,715,730 | 1,715,730 |
| Announcement Date | 4/28/21 | 4/27/22 | 4/21/23 | 3/29/24 | 3/27/25 | 4/17/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 1.21B | ||
| 36.25x | 12.94x | 27.18x | 0.55% | 1,089B | ||
| 28.59x | 6.53x | 18.09x | 2.01% | 643B | ||
| 33.13x | 7.75x | 15.94x | 2.61% | 465B | ||
| 20.2x | 4.86x | 12.04x | 2.72% | 359B | ||
| 22.65x | 5.84x | 14.57x | 2.74% | 303B | ||
| 22.03x | 4.53x | 12.8x | 1.93% | 267B | ||
| 14.79x | 5.48x | 11.3x | 3.38% | 226B | ||
| 25.81x | 6.73x | 11.86x | 2.57% | 212B | ||
| -48.4x | 5.8x | 32.01x | 2.45% | 167B | ||
| Average | 17.23x | 6.72x | 17.31x | 2.33% | 373.23B | |
| Weighted average by Cap. | 25.20x | 8.11x | 19.08x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 600812 Stock
- Valuation North China Pharmaceutical Company.Ltd
Select your edition
All financial news and data tailored to specific country editions
















